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Introduction
The hormone leptin, which is produced by adipocytes to signal the 
repletion of body energy (fat) stores, acts via the leptin receptor 
(LepRb) on specialized populations of brain neurons to control 
food intake, energy expenditure, and other metabolic parameters 
(1–4). The fall in circulating leptin concentrations during negative 
energy balance increases hunger and initiates an energy-sparing 
neuroendocrine program characterized by decreased sympathetic 
nervous system (SNS) tone and diminished activity of the thyroid, 
reproductive, and growth axes, among others. This response not 
only tends to replenish body energy stores by increasing feeding 
relative to energy utilization when food is available, but also pre-
serves remaining energy stores in the face of continued famine, 
increasing the chances of survival until food becomes available.
The withdrawal of leptin action from LepRb neurons in the 
hypothalamus mediates most of these orexigenic and energy-
sparing responses to negative energy balance (5). While brain stem 
sites contain many LepRb neurons, roles for most populations of 
brain stem LepRb neurons, including the largest population (locat-
ed in the periaqueductal gray [PAG]), remain undefined (6, 7).
In isolation, the energy-sparing neuroendocrine response 
to negative energy balance carries a potential risk, however. The 
reduction of energy stores coupled with decreased SNS tone 
impairs the ability to respond to acute, potentially life-threatening 
emergencies that require the robust mobilization of metabolic 
fuels, such as glucose. Thus, during negative energy balance, 
meeting acutely elevated metabolic needs requires a system 
that increases the drive to mobilize glucose beyond that which is 
required when energy reserves are replete. Furthermore, this sys-
tem must activate specifically in response to metabolic emergen-
cies without otherwise altering SNS tone and glucose mobilization 
(otherwise, this would blunt the energy-sparing response to nega-
tive energy balance). Indeed, we previously defined a system that 
augments the counterregulatory response (CRR) to hypoglycemia 
when energy stores are diminished: hypoglycemia activates chole-
cystokinin-containing (CCK-containing) neurons in the hindbrain 
parabrachial nucleus (PBN), which project to the ventromedial 
hypothalamic nucleus (VMN) (which plays a crucial role in the 
CRR) (8, 9). Some PBN CCK neurons contain LepRb; during nega-
tive energy balance, the withdrawal of leptin from these PBN Lep-
Rb cells augments their response to low glucose, enhancing glu-
cose mobilization during hypoglycemia without altering baseline 
endocrine function, energy balance, or glucose homeostasis (8).
We reasoned that other stimuli that signal the need for robust 
SNS activation and glucose mobilization might similarly engage 
the PBN→VMN circuit to meet acutely increased metabolic 
demands when energy stores are low. Because noxious stimuli 
(such as pain) increase blood glucose and often indicate the need 
for SNS activation and nutrient mobilization, we sought to under-
stand the potential role for hindbrain LepRb neurons in modulat-
ing the response to noxious stimuli in line with the repletion state of 
body energy stores. We find that LepRb neurons in the PAG (which 
plays crucial roles in responding to noxious stimuli; refs. 10–13) lie 
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by noxious stimuli, using the criterion of immunohistochemically 
detectable c-Fos induction in LeprCre Rosa26L10a-GFP (LepRbL10a-GFP; 
ref. 17) mice (Figure 1B), which express an L10a-GFP fusion pro-
tein in LepRb neurons, enabling their detection by αGFP immuno-
histochemistry (Figure 1 and Supplemental Figure 1; supplemen-
tal material available online with this article; https://doi.org/ 
10.1172/JCI90147DS1). Indeed, in LepRbL10a-GFP mice, formalin 
injection into the footpad promoted c-Fos accumulation in 38% 
of LepRbPBN neurons (562 ± 23 cells, mean ± SEM; n = 5) (Figure 
1, C and D), similar to the effect of glucoprivation by the injec-
tion of 2-deoxyglucose (2DG) (which mimics hypoglycemia at 
the cellular level) on these cells (568 ± 6 cells, mean ± SEM; n = 3) 
(Figure 1, E and F), suggesting that LepRbPBN neurons might play 
a role in modulating the response to noxious stimuli, in addition 
to hypoglycemia, during negative energy balance. Additionally, 
formalin injection activated approximately 23% of the LepRb neu-
rons (1862 ± 106 cells, mean ± SEM; n = 5) in the neighboring PAG 
(LepRbPAG neurons) (Figure 1, G and H), although glucoprivation 
did not activate LepRbPAG cells (Figure 1, I and J).
Integration of LepRbPAG neurons with the PBN→VMN circuit. 
Because noxious stimulus exposure activates both LepRbPAG and 
LepRbPBN neurons (while glucoprivation activates only LepRbPBN 
cells), and since the PAG receives and integrates signals related 
to noxious stimuli, we hypothesized that LepRbPAG neurons might 
upstream of the PBN→VMN circuit. Diminished leptin action on 
these LepRbPAG neurons augments the hyperglycemic response to 
noxious stimuli, ensuring appropriately elevated autonomic out-
put to mediate sufficient glucose mobilization in response to acute 
metabolic need under conditions of negative energy balance.
Results
Noxious stimuli activate LepRb neurons in the PBN and PAG. Pain 
and other noxious stimuli activate the SNS and promote the mobi-
lization of metabolic fuels to support the ability to cope with the 
stimulus-evoking event. Thus, short-term survival when faced 
with a noxious stimulus during negative energy balance requires a 
brain system that can overcome low SNS tone and depleted ener-
gy stores to support nutrient mobilization. Indeed, a 12-hour fast 
enhances the hyperglycemic response to the injection of 5% for-
malin into the footpad of the hind paw (a common noxious stimu-
lus model; refs. 14–16) (Figure 1A).
Since the withdrawal of leptin from leptin-inhibited LepRb 
neurons in the PBN (LepRbPBN cells) enhances SNS activation 
and glucose mobilization during hypoglycemia (8), mitigating the 
impairment of the CRR that would otherwise occur during nega-
tive energy balance, we sought to determine whether the LepRbPBN 
circuitry might similarly modulate the response to noxious stim-
uli. We thus examined the potential activation of LepRbPBN cells 
Figure 1. Hyperglycemic and c-Fos responses to noxious stimuli. (A) Ad libitum–fed (n = 10) and overnight-fasted (n = 8) C57BL/6 mice were injected with 
intra–hind paw formalin (5%, 20 μl), and blood glucose concentrations were measured over the subsequent 3 hours. Data are plotted as mean ± SEM. (B) 
LepRbeGFP-L10a mice were treated with (C, D, G, H) intra–hind paw formalin (n = 4, veh; n = 5, formalin) as in A or (E, F, I, J) 2DG (n = 5, veh; n = 4, 2DG) (500 
mg/kg, i.p.) and perfused under anesthesia. Brains were collected and sectioned; sections were stained for c-Fos (DAB, purple) and GFP (green). Images (C, 
E, G, I) are representative of 4–5 similar animals for each treatment. Graphs show colocalized cells/total LepRb cells, plotted as percentage, mean ± SEM. 
*P < 0.05. Scale bars: 100 μm. Data in panel A were analyzed by 2-way repeated-measures ANOVA with Fisher’s LSD post hoc test, and data in panels D, F, 
H, and J were analyzed by 1-tailed t test.
Downloaded from http://www.jci.org on November 15, 2017.   https://doi.org/10.1172/JCI90147
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 1 0 5jci.org   Volume 127   Number 8   August 2017
mCherry–containing local afferents of PBN-projecting LepRbPAG 
cells, especially in the PAG. We also observed afferents to the 
LepRbPAG→PBN circuit in more distant sites, including the dorsal 
raphe (DR) (Supplemental Figure 3); we observed few afferents 
elsewhere and none in the spinal cord, suggesting little or no direct 
input from peripheral nociceptive neurons. Thus, most of the neu-
ral signals to the LepRbPAG→PBN circuit enter via other PAG cells.
Since LepRbPAG cells project to the PBN and contain stimu-
latory neurotransmitters (such as Glu and CCK), activation of 
LepRbPAG cells should stimulate neurons in the PBN. To test this, 
we utilized AAV-hMD3q, which mediates the Cre-dependent 
expression of the Gq-coupled designer receptor exclusively acti-
vated by designer drugs (DREADD), permitting the clozapine-N- 
oxide–stimulated (CNO-stimulated) activation of Cre-expressing 
neurons in the region where the virus is injected. We injected 
AAV-hMD3q separately into the PAG or PBN of LeprCre mice and 
examined the induction of c-Fos in these regions following the 
administration of CNO (Supplemental Figure 4). CNO treatment 
of PAG-injected mice promoted the accumulation of c-Fos in the 
PAG and PBN, while CNO promoted robust c-Fos accumulation 
in the PBN of PBN-injected mice, but little in the PAG. Thus, 
LepRbPAG neurons lie afferent to and stimulate PBN neurons.
To determine whether PAG neurons, including LepRbPAG cells, 
lie in direct synaptic contact with the LepRbPBN→VMN circuit, we 
injected AAV-TVA+G into the PBN of LepRbL10a-GFP mice, followed 
by the injection of Rabies-ΔG-mCherry into the VMN to medi-
ate the infection of VMN-projecting LepRbPBN (LepRbPBN→VMN) 
neurons specifically and to label the cells that lie 1 synapse affer-
represent the means by which information regarding noxious 
stimuli enters the PBN→VMN circuit. To test this, we injected 
AAV-SynGFP (which mediates the Cre-inducible expression of a 
synaptophysin-GFP fusion protein to reveal synaptic terminals) 
into the PAG of LeprCre mice; at the same time, we injected AAV-
map2c-dsRed (which mediates the Cre-inducible expression of 
a map2c-dsRed fusion protein that identifies the dendritic tree) 
into the PBN of the same mice (Figure 2A). This revealed the pro-
jection field of LepRbPAG neurons, which densely innervate the 
PBN, and demonstrated that many of the synaptic terminals from 
these cells lie in the PBN region that contains the dendritic tree of 
LepRbPBN neurons (Figure 2, B and C). We also found terminals 
from LepRbPAG neurons in the dorsomedial nucleus of the hypo-
thalamus (DMH) and dorsomedial thalamus (Supplemental Fig-
ure 2), although these were much sparser than those in the PBN.
We employed rabies-mediated monosynaptic retrograde trac-
ing (18) to examine the circuitry of PBN-projecting LepRbPAG cells. 
In this system, the injection of the AAV-TVA+G helper virus medi-
ates expression of TVA in Cre-containing neurons to permit their 
infection by a pseudotyped, G-deleted, mCherry-expressing rabies 
virus (Rabies-ΔG-mCherry). AAV-TVA+G also mediates the Cre-
dependent expression of G, enabling the passage of Rabies-ΔG-
mCherry one synapse retrograde to the Cre-expressing neuron. 
We injected AAV-TVA+G into the PAG of LeprCre-eYFP mice and then 
delivered Rabies-ΔG-mCherry into the PBN (Figure 2, D–H). This 
not only infected many LepRbPAG cells with Rabies-ΔG-mCherry 
(consistent with our identification of the PBN as a major projection 
target of LepRbPAG cells), but also revealed numerous Rabies-ΔG-
Figure 2. PAGLepRb neurons project to the PBN. (A) LeprCre mice were injected with AAV-Syn-GFP into the PAG and AAV-map2c-dsRed into the PBN. The 
mice were perfused; (B and C) brains were collected, sectioned, and stained for GFP (green) and dsRed (red). Images are representative of 3 similar cases. 
Dashed lines indicate the boundaries of the PAG and PBN. Box in B shows the zoomed-in area represented in C. (D) LeprCre/eYFP mice were injected with 
AAV-TVA+G into the PAG; 2 weeks later, defective pseudotyped mCherry-expressing rabies virus (Rabies-ΔG-mCherry) was injected into the PBN. Five 
days later, mice were perfused and brains were collected and sectioned. Brain sections were stained for GFP (green) and dsRed (red) (E and F). Images are 
representative of 4 similar cases. H shows an enlarged image of G. Scale bars: 100 μm. IC, inferior colliculus; Aq, cerebral aqueduct.
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tially noxious stimuli that reflect increased metabolic demand, 
we examined the ventilatory response to hypercapnia in ani-
mals expressing hM3Dq in LepRbPAG neurons (Figure 4F). CNO 
administration increased breathing frequency in 3% CO2, but not 
in room air, consistent with augmented SNS drive to respiratory 
centers. Thus, in addition to increasing SNS outflow to the adre-
nal gland and elevating blood glucose concentrations, activation 
of LepRbPAG cells augments the ventilatory response to hypercap-
nia, consistent with a role for these cells in promoting appropriate 
autonomic responses when metabolic demand is acutely elevated.
Ablation of LepRb from the PAG augments the hyperglycemic 
and ventilatory responses to noxious stimuli. To determine whether 
leptin action via brain stem LepRb neurons modulates glucose 
mobilization in response to noxious stimuli, we evaluated the 
hyperglycemic responses to noxious stimuli in LepRbCCKKO mice 
(CckCre Leprfl/fl), in which LepRb is ablated from CCK-expressing 
brain stem neurons (including LepRbPBN cells, a substantial num-
ber of LepRbPAG neurons, and a smaller number of LepRb neurons 
in the Edinger-Westfall [EW] nucleus) (8) (Figure 5A). As we pre-
viously showed (8), the hyperglycemic response to glucoprivation 
is accentuated and prolonged in LepRbCCKKO mice (Figure 5B), 
consistent with the role for LepRbPBN neurons in augmenting the 
CRR to glucoprivation when leptin action is low. Furthermore, 
LepRbCckKO mice demonstrated an exaggerated hyperglycemic 
response to formalin injection, revealing that decreased leptin 
action on LepRbCCK neurons augments glucose mobilization in 
response to noxious stimuli (Figure 5C).
Since leptin action in LepRbCCKKO mice is only partially inter-
rupted in the PAG and is also ablated in the EW and PBN (8), we 
sought to determine the role of PAG leptin action specifically in 
the response to noxious stimuli. We thus injected AAV-Cre or 
AAV-mCherry (control) into the PAG of Leprfl/fl mice, disrupting 
LepRb specifically in the PAG (LepRbPAGKO mice) to reveal the 
role of LepRbPAG neurons in leptin action (Figure 6A and Supple-
mental Figure 7). Food intake, body weight, glucose tolerance, 
insulin-induced hypoglycemia, and the hyperglycemic response 
to glucoprivation were not altered in LepRbPAGKO mice (Figure 6, 
B–F), consistent with the notion that LepRbPBN cells (rather than 
LepRbPAG neurons) augment the CRR to hypoglycemia/glucopri-
vation when leptin action is decreased.
The hyperglycemic response to formalin injection was sig-
nificantly enhanced in LepRbPAGKO mice, however, revealing that 
ent to these cells (Figure 3A). This analysis revealed Rabies-ΔG-
mCherry–infected cells in the PBN as well as identifying afferents 
of LepRbPBN→VMN neurons in the PAG and in several other nearby 
areas (Figure 3B). We also observed afferents of LepRbPBN→VMN 
neurons in more distal regions, including the DR, the paraven-
tricular nucleus of the hypothalamus, the bed nucleus of the stria 
terminalis, and the central nucleus of the amygdala (CeA) (Sup-
plemental Figure 5). In addition to demonstrating the expected 
infection of many GFP-containing LepRbPBN cells by intra-VMN 
Rabies-ΔG-mCherry (Figure 3C), some (<10%) of the PAG neu-
rons afferent to the LepRbPBN→VMN cells contained GFP (Figure 
3D), revealing that LepRbPAG neurons are among the PAG cells that 
project to and synapse on VMN-projecting LepRbPBN cells.
LepRbPAG neurons activate the SNS and increase blood glucose. 
Taken as a whole, our data suggest that LepRbPAG cells project to 
and activate neurons in the PBN→VMN circuit, implying that 
activating LepRbPAG neurons should mimic the CRR, activating 
the SNS and increasing blood glucose concentrations. To deter-
mine the physiologic and behavioral responses to the activation of 
LepRbPAG and LepRbPBN cells, we injected AAV-hMD3q into the 
PAG or PBN of LeprCre mice and examined their responses to CNO 
(Figure 4A). We observed 1663 ± 364 (mean ± SEM; n = 7) PBN 
hM3Dq-expressing cells and 2853 ± 422 (mean ± SEM; n = 9) PAG 
hM3Dq-expressing cells in our study. We initially observed that 
activation of either set of LepRb neurons increased locomotor 
activity (Supplemental Figure 6), consistent with increased SNS 
drive following the activation of these cells. Indeed, CNO admin-
istration to mice expressing hMD3q either in LepRbPBN or LepRbPAG 
cells increased adrenal sympathetic nerve activity (SNA) (Figure 4, 
B and C), although the activation mediated by the LepRbPBN neu-
rons became statistically significant at earlier times than for the 
LepRbPAG neurons. Furthermore, activation of LepRbPAG or 
LepRbPBN neurons increased blood glucose concentrations (Fig-
ure 4, D and E). Thus, LepRbPAG neurons, like LepRbPBN cells, pro-
mote SNS activity and increased blood glucose — consistent with 
a role for LepRbPAG neurons in controlling glucose mobilization in 
response to activating stimuli (e.g., noxious stimuli).
Hypercapnia normally signifies an increase in cellular respi-
ration/metabolic demand that is not appropriately compensated 
by breathing; the PAG participates in the ventilatory response to 
hypercapnia (19–22). To determine whether LepRbPAG neurons 
might also participate in other autonomic responses to poten-
Figure 3. PAGLepRb neurons innervate VMN-projecting PBNLepRb neurons. (A) LepRbeGFP-L10a mice were injected with AAV-TVA+G into the PBN, followed by defec-
tive pseudotyped mCherry-expressing rabies virus (Rabies-ΔG-mCherry) injection into the VMN. Five days later, the mice were perfused, and brains were col-
lected, sectioned, and stained for GFP (green) and dsRed (red) (B–D). Shown are images representative of 4 similar cases: (B) PAG, PBN, and surrounding areas 
(mCherry only); (C) PBN (merged image); (D) PAG (merged image). Dashed lines in B denote the boundaries of the PAG and PBN. Scale bars: 100 μm.
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a constitutive AAV-TetTOX-GFP (which expresses 
tetanus toxin, preventing neurotransmitter release 
and effectively silencing all PBN neurons, plus GFP) 
in mice that also received injections of AAV-hM3Dq 
in the PBN of LeprCre mice (Figure 7A. As previously, 
CNO increased blood glucose concentrations in mice 
expressing hM3Dq in LepRbPAG neurons plus control 
virus in the PBN (Figure 7, B and C). In contrast, the 
hyperglycemic effect of CNO was diminished in 
mice expressing hM3Dq in LepRbPAG neurons plus 
AAV-TetTOX-GFP in the PBN. Thus, PBN-mediated 
neurotransmission plays a crucial role in the control 
of blood glucose by LepRbPAG neurons.
Thus, the withdrawal of leptin action from 
LepRbPAG cells enhances glucose mobilization and 
other autonomic responses to noxious stimuli (pain, 
hypercapnia) that signal acutely increased metabol-
ic demand, consistent with a crucial role for these 
cells in the brain system that promotes adequate 
glucose mobilization and SNS activity when meta-
bolic requirements increase acutely during negative 
energy balance (Figure 7D).
Discussion
We have identified a role for low leptin during negative energy 
balance in augmenting the autonomic response to noxious stimuli 
that signify acute unmet metabolic needs, thus ensuring that the 
drive to mobilize glucose is sufficient to overcome the additive 
effects of low SNS tone and depleted body energy stores (Figure 
1A). Hence, this system can mitigate the detrimental effects of 
what would otherwise be diminished glucose mobilization during 
metabolic challenges in the face of the low SNS tone and depleted 
energy reserves that accompany negative energy balance.
Our findings also reveal the neural circuit that mediates this 
function (Figure 7D), beginning with LepRbPAG neurons — the 
largest group of LepRb neurons in the brain stem, whose function 
was previously unknown (6, 8). Noxious stimuli (which indicate 
the need to mobilize glucose to support appropriate responses) 
decreased leptin action on LepRbPAG cells enhances glucose mobi-
lization during noxious stimuli (Figure 6G). Importantly, however, 
measures of pain perception and sensitivity were not altered in 
LepRbPAGKO mice (Supplemental Figure 8), indicating that leptin 
action via the PAG controls glucose mobilization during noxious 
stimuli, but does not alter the threshold for noxious stimulus per-
ception. Furthermore, the breathing frequency of LepRbPAGKO 
mice was not different from that of controls in room air, but 
increased compared with control animals in the presence of 3% 
CO2 (Figure 6H), consistent with the notion that decreased leptin 
action on LepRbPAG cells enhances the autonomic hyperventilatory 
response to hypercapnia.
Our tracing experiments (Figures 2 and 3) suggest that projec-
tions from LepRbPAG cells to the PBN could mediate the actions of 
these cells. To test this directly, we injected control AAV-GFP or 
Figure 4. Activation of PAGLepRb increases adrenal SNA, 
blood glucose, and respiratory responses to hypercapnia. 
(A) LeprCre (CC) animals were injected with AAV-hM3Dq  
into the PBN (left panels) or PAG (right panels). (B and C) 
PBN (B) (n = 8, C57BL/6 [C57]; n = 6, CC) and PAG (C)  
(n = 7, C57BL/6; n = 9, CC) AAV-hM3Dq–injected C57BL/6 
or LeprCre (Cre) animals were treated with CNO during SNA 
recording. Data were broken down into 5-minute bins for 
analysis; data are plotted as mean ± SEM; *P < 0.05. (D 
and E) PBN (D) or PAG (E) AAV-hM3Dq–injected LeprCre mice 
were injected with either CNO or vehicle and blood glucose 
sampled. Data are presented as mean ± SEM; *P < 0.05. 
(F) PAG-injected LeprCre mice were treated with either CNO 
or vehicle, and respiratory frequency was monitored at 
baseline and during exposure to 3% CO2 in a whole-body 
plethysmograph. Data are plotted as mean ± SEM; *P < 
0.05. Data in panels B–E were analyzed by 2-way repeated-
measures ANOVA with Fisher’s LSD post hoc test. Data in 
panel F were analyzed using a 1-tailed t test.
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activate LepRbPAG neurons, which project to the PBN→VMN cir-
cuit and promote SNS outflow and glucose mobilization. The 
withdrawal of leptin action from LepRbPAG cells enhances glucose 
mobilization in response to noxious stimuli, revealing a role for 
these cells in ensuring adequate glucose mobilization in response 
to acute demands when leptin levels are low due to negative ener-
gy balance. In addition to the obvious survival benefit conferred 
by this system in the wild, it may also complicate the analysis of 
glycemic control, especially by inexperienced researchers who 
inadvertently provoke noxious stimuli while measuring blood glu-
cose in fasted or leptin-deficient animals.
Interestingly, the time course with which the hM3Dq-mediated 
activation of LepRbPAG neurons augments blood glucose is delayed 
relative to some acute sympathetic responses to noxious stimuli 
(such as those that increase heart rate and blood pressure). This 
finding may indicate that the negative energy balance–mediated 
augmentation of glucose mobilization in response to noxious stim-
uli operates via a different, more slowly acting system and thus with 
a delayed time course compared with these other parameters. This 
would suggest that LepRbPAG neurons and their circuits play more 
important roles in response to stimuli that develop over or last for 
many minutes, thus indicating the need for more sustained glucose 
mobilization (rather than mediating the immediate response to 
noxious stimuli that might be adequately met with an initial burst 
of SNS activation). Alternatively, activation of LepRbPAG neurons or 
the circuits they subserve might require other contextual cues to 
mediate the more immediate augmentation of blood glucose.
Since activating LepRbPAG neurons or ablating LepRb in these 
cells also augments the ventilatory response to hypercapnia 
(which signals high metabolic demand relative to ventilation), 
LepRbPAG cells presumably match ventilatory drive to the needs of 
acutely increased metabolic demand when leptin levels are low. 
These functions for LepRbPAG cells are consistent with the general 
role for the PAG in mediating sympathetic activation (23–25) and 
many autonomic responses to pain (12, 26) as well as the control of 
respiratory rate and the response to hypercapnia (19–22).
The PAG is a large nucleus, different regions of which play 
relatively distinct roles in autonomic and behavioral control. The 
ventral PAG receives projections primarily from the spinal cord and 
brain stem and mediates passive coping responses, such as freezing 
and decreasing blood pressure (25, 26). In contrast, the dorsal PAG 
(especially the caudal dorsal PAG) receives projections from sen-
sory processing centers and mediates active coping responses, such 
as increased SNS output and flight (23–26). The majority of the PAG 
LepRb cells lie within this caudal dorsal region of the PAG, which 
also contains the vast majority of noxious stimulus–activated LepRb 
neurons. Due to the size of the PAG, it is not possible to target the 
entire length and depth of this nucleus by injection; we focused on 
the caudal dorsal regions with our injections, using 2 injections per 
side (4 injections total per mouse) to sufficiently target the relevant 
populations of LepRbPAG neurons. The role of LepRbPAG cells in pro-
moting SNS outflow, activity, glucose mobilization, and increased 
respiratory rate are consistent with the known output of this region. 
Since LepRb neurons in other areas of the PAG (and in adjoining 
structures, such as the DR) could mediate distinct processes, it will 
be interesting to define their functions as well.
This LepRbPAG→PBN→VMN circuit demonstrates multiple 
levels of specificity. Since it is engaged by the removal of leptin 
action, it is activated specifically during negative energy bal-
ance, when it is required to augment the drive to mobilize glu-
cose. Also, it is activated only during times of acute need (i.e., it 
does not augment glucose mobilization in the absence of a nox-
ious stimulus or another inciting event). Furthermore, the overall 
LepRbPAG→PBN→VMN system is specific for stressors that indi-
cate an acute metabolic challenge (e.g., noxious stimuli, elevated 
CO2, or in the case of the PBN, glucoprivation); this system is not 
activated during restraint stress (8) or in response to acute hypo-
tension (data not shown), for instance.
While restraint stress does not activate LepRbPAG or LepRbPBN 
cells, it activates LepRbEW cells (27). Since LepRb is ablated from 
LepRbEW cells in LepRbCCKKO mice, but the glycemic response to 
restraint stress is not altered in these animals (8), LepRbEW cells must 
modulate different outputs than do LepRbPAG and LepRbPBN cells. 
Indeed, projections from EW cells target the striatum (28, 29) rather 
than the VMN, suggesting a potential role for LepRbEW cells in modu-
lating motivated behaviors, rather than metabolic fuel mobilization.
Figure 5. LepRbCCKKO mice exhibit exaggerated hyperglycemic 
responses to formalin injection. (A) LepRbCCKKO mice were gen-
erated by crossing CckCre onto the Leprfl background. (B) Leprfl/fl  
(control) (n = 12) and LepRbCCKKO (n = 10) mice were treated with 
2DG (500 mg/kg, i.p.) and monitored for blood glucose. (C) A sep-
arate group of animals was treated with intra–hind paw formalin 
(5%, 20 μl) (n = 17, control; n = 13, LepRbCCKKO), and blood glucose 
was monitored. Data are plotted as mean ± SEM; *P < 0.05. Data 
in panels B and C were analyzed with 2-way repeated-measures 
ANOVA with Fisher’s LSD post hoc test.
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The output of the LepRbPAG→PBN→VMN circuit is largely spe-
cific for the augmentation of SNS outflow: this brain stem circuit 
does not represent a mechanism by which leptin modulates food 
intake, body weight, or metabolism at baseline, since none of these 
parameters were altered in LepRbCCKKO or LepRbPAGKO mice. Fur-
thermore, our data reveal that leptin action on LepRbPAG cells does 
not alter noxious stimulus perception or responding, since the tail-
flick and withdrawal responses are not changed in the LepRbPAGKO 
mice. This is consistent with our finding that pain-sensing neurons 
in the spinal cord do not directly synapse 
on LepRbPAG cells. In addition to noxious 
stimuli and hypercapnia, it is possible that 
other signals of acutely elevated metabolic 
demand that are integrated by the PAG 
might engage LepRbPAG neurons and their 
circuitry, as well.
Leptin modulates the LepRbPAG→ 
PBN→VMN circuit at 2 points — the PAG 
and the PBN. That the circuits down-
stream of LepRbPAG and LepRbPBN neurons 
overlap substantially makes teleological 
sense, since both circuits control similar 
physiologic end points (SNS outflow and 
glucose mobilization) and must therefore 
converge on the same output (the VMN 
in this case) to mediate their overlapping 
physiologic functions. This is not dis-
similar to the convergence of DMH and 
arcuate nucleus (ARC) LepRb-expressing 
neurons on common pathways that con-
trol food intake and overall energy expen-
diture. While on the surface, it may seem 
redundant for leptin to act at multiple 
sites within a single circuit, leptin acts at 
least somewhat distinctly at these 2 sites; 
PAGLepRb neurons do not contribute to 
the CRR to hyperglycemia and are only 
involved in responding to noxious stimuli. Thus, leptin action on 
LepRbPAG cells does not alter the CRR to hypoglycemia, whereas 
PBN leptin action does.
The expression of LepRb in the PAG (in addition to the PBN) 
suggests that PBN LepRb on its own may not adequately augment 
SNS activation and glucose mobilization in response to noxious 
stimuli. If so, this could reflect the need for cell-autonomous 
leptin action to modulate the cellular response to the noxious 
input. While silencing all PBN neurons blocked the hyperglyce-
Figure 6. Deleting LepRb in the PAG exagger-
ates hyperglycemic responses to formalin 
and respiratory responses to hypercapnia. (A) 
Leprfl/fl mice on the Cre-inducible eGFP-L10a 
background were injected with AAV-Cre into  
the PAG to generate LepRbPAGKO mice (n = 13,  
control; 14, LepRbCCKKO). Body weight (B) 
and food intake (C) of control-injected and 
LepRbPAGKO mice were monitored weekly. In 
separate experiments, mice were treated with 
(D) glucose (2 g/kg, i.p.), (E) insulin (1.2 U/kg, 
i.p.), (F) 2DG (250 mg/kg, i.p.), and (G) formalin 
(20 μl, hind paw) and blood glucose concentra-
tions were followed. (H) Respiratory rate was 
measured at baseline and following exposure 
to 3% CO2. Data are plotted as mean ± SEM; 
*P < 0.05. Data in panels B–G were analyzed 
using 2-way repeated-measures ANOVA with 
Fisher’s LSD post hoc test. Data in panel H were 
analyzed using a 1-tailed t test.
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neither does leptin alter that activity of LepRbPAG 
neurons in ex vivo slice preparations (data not 
shown). We previously observed that leptin inhib-
its LepRbPBN cells under low-glucose conditions 
(8), but we were unable to detect leptin-mediated 
inhibition of these cells in normal glucose, sug-
gesting that a relevant activating stimulus might be 
required to observe the inhibitory effect of leptin on 
these cells. Hence, the effect of leptin on LepRbPAG 
cells might also be detectable only during activa-
tion of the neurons by other stimuli (e.g., by pain 
or hypercapnia). Unfortunately, it is not possible 
to stimulate ex vivo slice preparations with pain or 
hypercapnia, since the neurons that initially detect 
these stimuli lie remote to the LepRbPAG cells. Thus, 
leptin might inhibit LepRbPAG neurons, but techni-
cal issues prevent us from detecting this change in 
ex vivo slices. Since LepRbPAG neurons are largely 
glutamatergic (data not shown), the activation of 
these cells by leptin could also stimulate an inhibitory interneu-
ron to mediate the observed effects. It is also possible that leptin 
does not directly or acutely alter the firing rate of LepRbPAG neu-
rons, but rather mediates a transcriptional change that alters the 
magnitude of the response evoked by activating stimuli. Addi-
tionally, it is theoretically possible that the PAG could contain 
multiple subtypes of LepRb neurons.
Despite the power and utility of the genetic tools that we have 
employed to dissect the function of LepRbPAG neurons, it must be 
recognized that these manipulations are artificial and extreme; 
the level of activation, silencing, or degree of leptin insensitiv-
ity that these tools produce is unlikely to be recapitulated under 
physiologic circumstances. Nonetheless, the consistency of the 
mic effect of activating LepRbPAG cells, silencing LepRbPBN cells 
did not (data not shown); thus LepRbPAG neurons must activate 
non-LepRb PBN→VMN cells as well as LepRbPBN cells to enhance 
glucose mobilization in response to noxious stimuli. Indeed, for-
malin activates a large number of non-LepRb PBN neurons that lie 
in the vicinity of LepRbPBN neurons, consistent with the notion that 
LepRbPBN cells represent only a subset of the PBN cells that make 
up the circuit downstream of LepRbPAG neurons.
While the similar results of activating LepRbPAG neurons and 
removing LepRb from these cells suggests that the lack of leptin 
signaling activates LepRbPAG neurons (i.e., that leptin inhibits 
LepRbPAG neurons), leptin and fasting each fail to detectably alter 
the activity of LepRbPAG cells by c-Fos immunohistochemistry; 
Figure 7. PAGLepRb neurons act via the PBN to increase 
blood glucose. (A) LeprCre mice were injected with AAV-
hM3dq in the PAG and either a GFP-expressing control virus 
(n = 7) or AAV-TetTOX-GFP (n = 10) to constitutively express 
GFP or GFP plus TetTOX in the PBN, respectively. All mice 
were randomly assigned to receive vehicle control or CNO; 
mice received the other treatment the following week (B 
and C). Glycemic responses following vehicle injection were 
not different between groups and were thus combined 
into a single control group. (D) Our data demonstrate that 
PAGLepRb neurons act via the PBN to mobilize glucose and 
increase adrenal SNA when activated by noxious stimuli 
such as pain and hypercapnia. In the presence of sufficient 
energy stores, leptin inhibits these neurons to limit sym-
pathetic activation and hyperglycemia to appropriate levels 
during the response to noxious stimuli. When energy stores 
are depleted, however, loss of leptin inhibition of PAGLepRb 
neurons augments sympathetic and glycemic responses 
to noxious stimuli to ensure a sufficient glucose mobiliza-
tion in response to noxious stimuli, despite reduced overall 
sympathetic tone and the depletion of energy stores. Data 
are plotted as mean ± SEM; groups with different letters 
are significantly different. P < 0.05. Data in panel B were 
analyzed using 2-way repeated-measures ANOVA with 
Fisher’s LSD post hoc test. Data in panel C were analyzed 
using 1-way ANOVA with Fisher’s LSD post hoc test.
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30% sucrose for at least 1 day. Brains were cut into 30-μm sections 
on a freezing microtome in 4 series and stored in antifreeze solu-
tion (25% ethylene glycol, 25% glycerol). Sections were washed with 
PBS and then treated sequentially with 1% hydrogen peroxide/0.5% 
sodium hydroxide, 0.3% glycine, and 0.03% sodium dodecyl sulfate. 
Pretreatment was followed by an hour in blocking solution (PBS con-
taining 0.1% Triton X-100, 3% normal donkey serum), then overnight 
incubation in blocking solution containing rabbit anti-c-Fos (sc-52, 
Santa Cruz Biotechnology Inc., 1:1000) and/or chicken anti-GFP 
(GFP-1020, Aves, 1:1000), rabbit anti-dsRed (632496, Living Col-
ors, 1:1000), rabbit anti-pSTAT3 (91455, Cell Signaling Technology, 
1:500), or rabbit anti-calcitonin gene-related peptide (anti-CGRP) 
(PC205L, Millipore, 1:1000) at room temperature. The next day, 
the sections were incubated with fluorescent secondary antibodies 
(Molecular Probes, 1:200) or with biotinylated secondary antibody 
(Jackson Immunoresearch, 1:200) followed by ABC amplification 
(Vector Laboratories, 1:500) and diaminobenzadine (Thermo Sci-
entific) reaction. The sections treated with biotinylated secondary 
antibody were exposed to avidin/biotin complex solution followed by 
diaminobenzadine reaction. The sections were mounted onto slides 
coverslipped with Fluoromount-G (Southern Biotech). Images were 
collected on an Olympus Bx53 microscope, and the number of immu-
noreactive cells were counted using Adobe photoshop. The number 
of c-Fos–positive nuclei colocalizing with GFP-expressing cells were 
counted, along with total GFP-containing cells, and were expressed as 
a percentage of all GFP-expressing cells within the region of interest.
Phenotypic studies. Body weight and food intake were monitored 
weekly in animals starting at 3 weeks after surgery. Glycemic mea-
sures, including glucose tolerance test (GTT) (2 g/kg body weight, 
i.p.), insulin tolerance test (ITT) (1.2 unit/kg body weight, Humulin, 
Eli Lilly, i.p.), 2DG (Sigma-Aldrich) challenge (250 or 500 mg/kg body 
weight, ip), and formalin challenge (20 μl; 5% formalin, intra–hind 
paw) were determined in 12- to 18-week-old animals by analyzing tail 
vein blood with a OneTouch Ultra 2 glucometer (Johnson & Johnson). 
For formalin challenge, mice were not included in the study unless 
there was visual inspection confirming inflammation of the hind paw 
to control for a missed injection. To measure leptin-induced pSTAT3, 
animals were fasted for 24 hours prior to leptin administration. For 
fasting modulation of hyperglycemic responses to intra–hind paw for-
malin injection, mice were fasted for 12 hours. For DREADD studies, 
CNO (Tocris Biosciences) was administered via i.p. injection at 0.3 
mg/kg body weight.
Stereotaxic injections. Eight- to fourteen-week-old animals were 
anesthetized with 1.5%–2% isoflurane in preparation for craniotomy. 
The skull was exposed, bregma and lambda were leveled, a hole was 
drilled, and we injected the contents of a pulled pipette at the coordi-
nates of our target for approximately 25 nl/min. For the PBN, 100 nl of 
virus was injected at anteroposterior (AP) –4.85, mediolateral (ML) ± 
1.2, and dorsoventral (DV) –3.3. For the PAG, 100 nl of virus was inject-
ed at 4 separate coordinates per animal (AP: –4.9, ML: 0, DV: 0.7; AP: 
–4.8, ML: ± 0.6, DV: 0.95; AP: –4.7, ML: 0, DV: 0.8). For the VMN, 50 
nl was injected at AP: –1.1, ML: ± 0.35, DV: –3.3. After 5 minutes, to 
allow the virus to diffuse into the brain, the pipette was raised slowly 
out of the hole in the skull, the hole in the skull was filled with bone 
wax, and the skin was closed with surgical sutures (Henry Schein). 
Analgesics were administered prophylactically to all mice to prevent 
postsurgical pain. The animals were allowed 4 weeks to recover from 
results produced by the various approaches undertaken suggests 
the veracity of our conclusions.
In addition to revealing the function of the largest population 
of LepRb neurons in the brain stem (LepRbPAG neurons), which 
had not, to our knowledge, previously been studied, our findings 
define a new component of the response to fasting and a new physi-
ologic role for leptin: in addition to the hypothalamically mediated 
energy-sparing neuroendocrine response to starvation, low leptin 
augments the activation of a LepRbPAG→PBN→VMN circuit that 
ensures adequate SNS drive and glucose mobilization to meet the 
metabolic needs associated with noxious stimuli or hypoglycemia 
during negative energy balance. In the future, it will be important to 
identify other stimuli that act via this system to augment SNS out-
flow during negative energy balance as well as to define the detailed 
mechanisms by which this circuit mediates glucose mobilization.
Methods
Animals. All mice were provided with food and water ad libitum unless 
noted otherwise and kept in a temperature-controlled room on a 
12-hour light/12-hour dark cycle. All experiments were carried out 
using approximately equal numbers of male and female mice. Animals 
were processed and studied in the order of their randomly assigned 
ear tags. Investigators were blinded to the genotype and/or treatment 
for all studies. All mice were genotyped via PCR across the poten-
tially mutated region prior to study. C57BL/6 animals originated from 
Jackson Laboratories, but all other mice were bred within our colony. 
LeprCre/Cre mice were on a C57BL/6 background, as previously described 
(8, 30–32). LepRbeGFP-L10a mice were generated by interbreeding com-
pound homozygous LeprCre/Cre Rosa26eGFP-L10a/eGFP-L10a mice. LepRbeYFP 
mice were generated by interbreeding compound homozygous 
LeprCre/Cre Rosa26eYFP/eYFP mice. LepRbCCKKO mice and their controls 
were generated by breeding male CckCre Leprfl/fl mice to female Leprfl/fl 
mice. Leprfl/fl mice for AAV-Cre injection were generated by interbreed-
ing homozygous Leprfl/fl mice. When possible, animals were randomly 
assigned to groups and investigators were blind to treatment.
Reagents. The AAV-map2c-dsRed was developed by cloning the 
coding sequences for the map2c-dsRed fusion protein (in reverse ori-
entation) into the base Cre-inducible AAV vector, using SacI and NheI 
restriction sites. AAV-map2c-dsRed stocks were prepared at the Uni-
versity of North Carolina (UNC) Vector Core (Chapel Hill, North Car-
olina, USA). The AAV-Syn-GFP and AAV-TVA+G helper viruses were 
previously described (33, 34); viral stocks were prepared at the UNC 
Vector Core. The Rabies-ΔG-mCherry was as previously described 
(18, 34) and was generated at the University of Michigan Viral Vector 
Core with the support of the Molecular Genetics core of the Michigan 
Diabetes Research Center (University of Michigan). AAV-hM3dq, 
AAV-mCherry, AAV-GFP, and AAV-Cre were purchased from the 
UNC vector core. AAV-TetTox-GFP was from the Stanford University 
Viral Vector Core (Stanford, California, USA).
Perfusion and immunohistochemistry. Brains were collected and 
processed as previously described (8). To reveal leptin-responsive 
neurons by pSTAT3, leptin was administered (5 mg/kg, i.p.) 2 hours 
prior to perfusion. For c-Fos studies, mice were exposed to a given 
stimulus 90 minutes prior to perfusion. After either stimulus exposure 
or leptin administration, mice were anesthetized with avertin prior 
to transcardial perfusion with PBS followed by 10% formalin. Brains 
were removed and placed into 10% formalin overnight, followed by 
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was recorded (36). As with the tail-flick test, 3 separate instances of 
this test were recorded and averaged for an individual data point.
Respiratory measurement. Baseline ventilation and the ventilatory 
response to hypercapnia were measured in freely moving, conscious 
14- to 18-week-old mice using a whole-body plethysmograph (Emka 
Technologies). Gas tanks of O2, N2, and CO2 were connected to the ple-
thysmograph and digitally controlled by the plethysmograph to deliver 
gas mixtures into each plethysmograph mouse chamber. Each mouse 
was placed inside the chamber for 20 minutes to acclimate. After 
acclimation, baseline ventilation was measured while the mice were 
exposed to room air (e.g., 21% O2, 79% N2, 0% CO2). To determine 
the ventilatory response to hypercapnia, the CO2 concentration inside 
the chamber was elevated to 3% for periods of 4 minutes, separated 
by 5-minute recovery periods in room air (similar to ref. 37), while 
real-time breathing frequency was recorded. As CO2 was increased, 
N2 was decreased to allow O2 levels to be stabilized at 21%. In total, 
mice remained in the plethysmograph for approximately an hour. All 
respiratory measures were recorded between 8 am and 1 pm. During 
recording, mice were continuously monitored by the investigator to 
ensure that they stayed awake (as the ventilation response is blunted 
by sleep; ref. 37). If a mouse fell asleep, the investigator aroused the 
animal by gently tapping on the chamber.
Statistics. Statistical methods were not used to predetermine 
sample sizes, but our sample sizes are similar to those in previously 
published studies using similar approaches (8, 17, 37–39). Sample 
sizes for groups that involved stereotaxic injection of specific popula-
tions of cells were 40% larger than for other groups to account for 
a 50%–60% bilateral hit rate. c-Fos data and activity data were ana-
lyzed by 1-tailed t test. Blood glucose data were analyzed by 2-way 
repeated-measures ANOVA with Fisher’s least significant difference 
(LSD) post hoc test. Adrenal SNA data were analyzed by 1-tailed t test 
of 5-minute bins across the experiment. No data were removed unless 
the injection was a miss or the animal was sick or injured at the time 
of the experiment (loss of >10% body weight). Data that did not fall 
under a normal distribution or equal variance were log transformed, 
then reanalyzed. Significance was set at P ≤ 0.05. All data were ana-
lyzed using SigmaStat (Systat).
Study approval. The procedures included in this manuscript were 
approved by the appropriate Committees on the Use and Care of Ani-
mals at the University of Michigan and the University of Iowa.
Author contributions
All authors edited the manuscript. JNF designed and contributed 
to the performance of all experiments, interpreted the data, ran the 
statistical tests, and wrote the manuscript. MGM also designed all 
experiments, interpreted the data, and wrote the manuscript. DA 
and RJS helped design and ran the respiratory measurement test-
ing shown in Figure 4 and Figure 6. WP designed and constructed 
the AAV-map2c-dsRed used for Figure 2. CP helped design and 
run the glucose tests shown in Figure 4 and Figure 5. TL contrib-
uted to the design and execution of the rabies tracing experiments. 
PBG aided in studies of PAG LepRb neuron regulation. JS helped 
run LepRbPAGKO experiments and validation of our mouse mod-
els used in Figure 6 and Supplemental Figure 7. MJ helped run 
PAG and PBN DREADD experiments used for Figure 4. DAM 
and KR helped design and run adrenal SNA experiments shown 
in Figure 4. MBA designed and constructed the rabies helper virus 
surgery before experimental manipulation. At 3 weeks after surgery, 
the animals were individually housed for experiments that included 
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Adrenal SNA. Adrenal SNA was assessed using multifiber nerve 
recording. Mice (14 to 20 weeks old) that received the DREADD-
hM3dq virus in either the PAG or PBN were initially anesthetized 
with i.p. administration of ketamine (91 mg/kg body weight) and xyl-
azine (9.1 mg/kg body weight). Intubation with PE-50 was performed 
to provide an unimpeded airway for the mouse to spontaneously 
breathe O2-enriched room air. Micro-renathane tubing (MRE-40, 
Braintree Scientific) was inserted into the right jugular vein for infu-
sion of the sustaining anesthetic agent: α-chloralose (initial dose: 12 
mg/kg, then sustaining dose of 6 mg/kg/h). Another MRE-40 tubing 
was inserted into the left carotid artery for continuous measurement 
of arterial pressure and heart rate. Core body temperature was main-
tained at 37.5°C. A retroperitoneal incision was made to gain access to 
the preganglionic nerve fibers that innervate the left adrenal gland. 
A single multifiber nerve filament was carefully placed on a bipolar 
platinum-iridium wire (40 gauge, A-M Systems) and then sealed with 
silicone gel (Kwik-Sil, WPI). The adrenal nerve signal (AdSNA) was 
amplified 105 times, with low- and high-frequency filter cutoffs at 100 
and 1 Khz, respectively. The amplified and filtered signal was routed 
to a data acquisition system (MacLab Model 8s), which counted the 
number of nerve spikes that exceeded a threshold level set just above 
the noise level each second. After allowing all hemodynamic parame-
ters to stabilize, a slow i.v. infusion of CNO was given over 60 seconds 
and adrenal SNA was continuously monitored for the next 30 min-
utes. Next, a slow infusion of vehicle (hydroxypropyl β cyclodextrin; 
5 μl/g body weight, i.v.) was given over 60 seconds and the adrenal 
SNA was continuously measured for next 30 minutes. Background 
noise was excluded in the assessment of adrenal SNA by correcting 
for postmortem activity.
Behavioral analyses. Activity of 18- to 22-week-old mice was deter-
mined in the open-field test. The mice were introduced to the open-
field chamber for 2 hours prior to experimentation. On the following 
day, the mice were introduced to the chamber for 1 hour of baseline 
measurement followed by activity recording 1 hour after injection. 
Data were analyzed as the total number of counts over this 1-hour peri-
od. Tail flick and hind paw latency were tested as previously described 
using a tail-flick test analgesia meter (IITC Life Science) (35). For the 
tail-flick test, mice were individually restrained during the test to 
determine the latency to remove the tail away from a 75-degree light 
on 3 separate instances; the average of the 3 instances was used as an 
individual data point. For the hind paw test, the mice were allowed 
to acclimate to a Plexiglass chamber for 1 hour prior to testing. The 
75-degree light was then concentrated on the hind paw of an immobile 
mouse, and the latency for the hind paw to move away from the light 
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